Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...
CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...
New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...
New trial data showed CagriSema led to 'superior' weight loss, but at a rate much less than original expectations of 25% Shares of Novo Nordisk A/S were getting hit hard in early Monday trading ...
"Recall that CagriSema is more difficult to manufacture than tirzepatide due to its dual-chamber device, and NVO's future manufacturing capacity is TBD," wrote Leerink Partners analyst David ...
The Danish pharmaceutical giant on Monday said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results